EV Nickel Inc. | WebDisclosure

BRIEF

published on 11/07/2024 at 07:35, 1 year 4 months ago

APONTIS PHARMA annonce une croissance de son chiffre d'affaires sur les 9 premiers mois de 2024 malgré des prévisions révisées

APONTIS PHARMA Prévisions Financières Croissance Des Revenus Combinaisons De Pilules Simples Collaboration Avec Novartis
BRIEF

published on 11/07/2024 at 07:35, 1 year 4 months ago

APONTIS PHARMA Reports Revenue Growth in 9M 2024 Amid Revised Forecast

Revenue Growth Financial Forecast APONTIS PHARMA Single Pill Combinations Novartis Collaboration
PRESS RELEASE

published on 11/07/2024 at 07:30, 1 year 4 months ago

APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024, with revenue guidance adjusted. Novartis collaboration boosts revenues. Full-year forecast slightly lowered

Revenue Growth APONTIS PHARMA Single Pill Combinations Full-year Forecast Novartis Collaboration
BRIEF

published on 10/30/2024 at 16:25, 1 year 4 months ago

APONTIS PHARMA's Boards Recommend Acceptance of Zentiva's Tender Offer

Tender Offer APONTIS PHARMA Shareholder Recommendation Financial Premium Zentiva
BRIEF

published on 10/30/2024 at 16:25, 1 year 4 months ago

Les conseils d'administration d'APONTIS PHARMA recommandent l'acceptation de l'offre publique d'achat de Zentiva

Offre Publique D'achat APONTIS PHARMA Prime Financière Zentiva Recommandation Aux Actionnaires
PRESS RELEASE

published on 10/30/2024 at 16:20, 1 year 4 months ago

Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva’s public tender offer
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva's public tender offer. Offer price of EUR 10.00 per share represents a premium. Acceptance period ends on 21 November 2024

Acquisition Tender Offer APONTIS PHARMA AG Recommendation Zentiva
PRESS RELEASE

published on 10/18/2024 at 13:37, 1 year 5 months ago

Original-Research: APONTIS PHARMA AG (von Montega AG): Halten (zuvor: Kaufen)
Zentiva bietet öffentliches Erwerbsangebot für APONTIS PHARMA zu 10 EUR an. Montega AG stuft Empfehlung von Kauf auf Halten um. Analyse der Übernahme und finanziellen Auswirkungen

Montega AG Aktien Finanzanalyse Zentiva Übernahmeangebot
BRIEF

published on 10/16/2024 at 12:00, 1 year 5 months ago

APONTIS PHARMA and Zentiva Forge Strategic Partnership

APONTIS PHARMA Public Purchase Offer Pharmaceutical Growth Zentiva Partnership Single Pill Strategy
BRIEF

published on 10/16/2024 at 12:00, 1 year 5 months ago

APONTIS PHARMA et Zentiva concluent un partenariat stratégique

Offre Publique D'achat APONTIS PHARMA Croissance Pharmaceutique Partenariat Zentiva Stratégie De La Pilule Unique
BRIEF

published on 10/16/2024 at 11:55, 1 year 5 months ago

APONTIS PHARMA et Zentiva signent un accord d'investissement

Offre Publique D'achat APONTIS PHARMA Accord D'investissement Industrie Pharmaceutique Zentiva

Published on 03/26/2026 at 22:05, 42 minutes ago

BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 47 minutes ago

Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 47 minutes ago

Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 1 hour 47 minutes ago

Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 21:00, 1 hour 47 minutes ago

Rocky Shore Closes Acquisition of Additional Mining Claims

View all ACCESSWIRE

Published on 03/26/2026 at 20:48, 1 hour 59 minutes ago

Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 3 hours 27 minutes ago

Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:13, 3 hours 34 minutes ago

Director Declaration
Published on 03/26/2026 at 19:09, 3 hours 38 minutes ago

2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 3 hours 38 minutes ago

2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)

View all EQS

Published on 03/26/2026 at 18:17, 4 hours 30 minutes ago

Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 4 hours 30 minutes ago

Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 4 hours 47 minutes ago

Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 4 hours 47 minutes ago

Calendrier financier 2026
Published on 03/26/2026 at 18:00, 4 hours 47 minutes ago

LABORATOIRES EUROMEDIS - Fin du contrat de liquidité

View all LES ECHOS COMFI WIRE

News